

PROSTATE CANCER RESEARCH PROGRAM



MISSION: Fund research that will eliminate death and suffering from prostate cancer and enhance the well-being of Service Members and their Families, Veterans and all the patients and caregivers who are experiencing the impact of the disease.

Congressional Appropriations
FY97-FY24:
\$2.37B total



“When I had a prostate cancer recurrence 18 years ago, I knew that my disease was terminal and that there were only

three FDA-approved drugs that could possibly extend my life and help maintain a decent quality of life, as well as a few radio-pharmaceutical types of drugs that would only make me feel even sicker. I also knew that these drugs would not work forever. Thanks to cutting-edge research in prostate cancer, much of which has been led by the innovative nature of the PCRPR, I remain, 18 years later, alive and healthy, being a productive member of my community. Not only am I still contributing to society, I also have a constantly growing list of available new drugs and treatments which provide me with optimism about my future.”

*Joel Nowak, Cancer ABCs, Inc.,
 FY14-FY24 Programmatic Panel Member*



SCOPE OF THE PROBLEM

Estimated **299,010** new diagnoses and **35,250** deaths from prostate cancer in 2024¹



Relatively slow-growing; **<15%** present the rapidly growing, aggressive form²






Available treatments can result in **urinary, bowel and sexual dysfunction**³

Significant population disparities in incidence and mortality rates⁴



RELEVANCE TO MILITARY HEALTH

MHS Medical Encounters for Prostate Cancer, 2013-2022⁵

	 Average Patients per Year	 Out-Patient Encounters	 Hospital Bed Days
Service Members	227	12,556	965
Other DOD Beneficiaries	72,617	3.54 million	108,689

PROGRAM PRIORITIES

The PCRPR remains focused on addressing the knowledge, research and clinical gaps that continue to make prostate cancer a global health issue

- Improve quality of life for those impacted by prostate cancer
- Define the biology of progression to lethal prostate cancer
- Develop new or improved therapies for lethal prostate cancer
- Advance health equity and reduce disparities

¹ American Cancer Society, Cancer Facts & Figures, 2024.

² Centers for Disease Control and Prevention. Prostate Cancer Incidence by Age and Stage at Diagnosis, United States—2001–2019. USCS Data Brief, no. 34. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2023.

³ American Society of Clinical Oncology. 2023. Prostate Cancer: Types of Treatment 2022. Alexandria, VA, December 14, 2022.

⁴ Giaquinto AN, et al. *CA Cancer J Clin* 72, no.3, 2022:202-229.

⁵ Military Health System (MHS) data from the Defense Medical Surveillance System, 2010-2022. The Armed Forces Health Surveillance Division, Defense Health Agency (DHA), Silver Spring, Maryland, January 2024.





For more information, visit: <https://cdmrp.health.mil/pcrp/>

PROGRAM IMPACT AND OUTCOMES



Prostate Cancer Clinical Trials Consortium

Coordinating impactful, collaborative clinical trials since 2006



- **Abiraterone** - For metastatic castration-resistant and castration-sensitive disease
- **Apalutamide** - For metastatic castration-sensitive and non-metastatic castration-resistant disease
- **Cabazitaxel** - For metastatic castration-resistant disease previously treated with docetaxel
- **Denosumab** - Prevention of skeletal-related events due to bone metastases from prostate cancer
- **Enzalutamide** - For metastatic castration-resistant and castration-sensitive disease, and high-risk non-metastatic castration-sensitive disease
- **Rucaparib** - For metastatic castration-resistant disease in patients with mutations in BRCA genes

Improving Health Equity and Patient Outcomes

Health Equity Research and Outcomes Improvement Consortium Awards combine the expertise of research scientists, clinicians and integrated members of the patient population to improve quality of life and/or equitable access to quality health care and reduce disparities.

iCCaRE for Black Men Consortium



- Includes Black men from the U.S., of African and Caribbean descent, and Africa
- Identifies social and biological factors affecting patient outcomes
- Develops technology to improve patient care and quality of life

PCaPH Africa1K Consortium



- Conducts community education and training through local outreach
- Creates biorepositories across southern and eastern African nations
- Assesses hormones, genomes and environmental exposures to understand impact on incidence and disease progression

IMPLEMENTATION SCIENCE

The PCRP seeks to accelerate advancements for patient care into widespread acceptance and routine practice.

New in FY24, the Implementation Science Award will

- Bridge gaps among research, clinical practice and health policy
- Improve patient outreach, outcomes and effectiveness of care
- Foster engagement with patient communities

Point of Contact: CDMRP Public Affairs

usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil